Lumida
/EMBC
⌘K
Embecta Corp

Embecta Corp

EMBC
$3.25USD↓-2.99%-0.10 today

MARKET CAP

192.8M

P/E (TTM)

1.3x

FWD P/E

1.6x

DAY RANGE

$3 – $3

52W RANGE

$3
$16

AI Summary

Stalk
StalkMedium

In a Stage 4 decline, EMBC shows exhaustion after the May capitulation, qualifying for a mean-reversion setup at intermediate-cycle lows. However, price remains extended below declining EMAs and the short-term trend is down, so immediate entry is unattractive. We will stalk for a clean consolidation resolution or a pullback into resistance zones before buying.

  • ↑3.08% dividend yield offers reliable cash returns
  • ↑Owen Mumford acquisition expected to contribute ~$30 M to FY 2026 revenue
  • ↓Q2 2026 revenue $222 M (-14.4% YoY) and U.S. sales plunged 29%
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Embecta Corp. (NASDAQ: EMBC) is a leading provider of medical devices, particularly focusing on diabetes management solutions with a specialization in insulin delivery systems. The company is currently navigating a transformative phase, aiming to diversify its product offerings and enhance its position in the growing GLP-1 therapy market. Embecta's recent acquisition of Owen Mumford Holdings Limited is a strategic move intended to integrate new technologies and expand its capabilities in drug delivery, placing the company at the forefront of the chronic care market.

Bull says

  • ↑3.08% dividend yield offers reliable cash returns
  • ↑Owen Mumford acquisition expected to contribute ~$30 M to FY 2026 revenue
  • ↑FY 2026 revenue guidance of $1.015–1.035 B with upside in FY 2027
  • ↑Restructuring plan aims to cut costs and stabilize margins
  • ↑GLP-1 therapy market could unlock >$100 M revenue by 2033
  • ↑High earnings yield and solid balance-sheet quality support valuation

Bear says

  • ↓Q2 2026 revenue $222 M (-14.4% YoY) and U.S. sales plunged 29%
  • ↓GAAP net loss of $4.1 M (EPS -$0.07) vs. prior $23.5 M profit
  • ↓93% dividend cut to $0.01 signals cash‐flow strain
  • ↓Stock dropped 57.8% following securities class-action filings
  • ↓Pen needle share loss amid generic competition pressures top line
  • ↓Negative growth outlook and high volatility deter risk-averse investors

Investment themes with EMBC

Demographics: Elderly Care↓ -0.26%

Services and products for aging population

UCB.BR · JNJ · AZN

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 04-27-2026neutral

Transcript signals

Bull points

  • Fiscal First Quarter 2026 Earnings Conference Call
  • We continue to demonstrate a strong commitment to ensuring broad and preferred access to our products for patients, particularly within the Medicare Part D channel, which remains an important and growing segment of the payer market serving senior citizens who represent a high percentage of people living with diabetes.
  • Effective January 2026, we contracted with an additional Medicare Part D payer for exclusive access to our products. In addition, we renewed our advantage formulary access with the top three Medicare Part D payers that we had existing relationships with.

Bear points

  • The slight year-over-year decline in adjusted gross profit and margin was primarily driven by the unfavorable year-over-year pricing dynamics that Deb mentioned earlier and mix.
  • The small year-over-year decrease in adjusted operating income is primarily due to the decline in adjusted gross profit that I just mentioned, coupled with an increase in R&D expenses that is associated with a variety of projects underway at the company, including the development of market-appropriate pen needles and syringes, the development of a pen injector, as well as project costs associated with becoming cannula independent.
  • we currently expect that we'll be closer to the lower end of that range.
Read full transcript analysis ›